Summary
Johnson & Johnson (JNJ) reported its 2025 fiscal year results, highlighting continued growth across its two primary segments: Innovative Medicine and MedTech. The company's overall sales increased by 6.0% to $94.2 billion, driven by strong volume growth, partially offset by pricing pressures and foreign currency impacts. The Innovative Medicine segment saw a 6.0% sales increase, propelled by strong performance in Oncology products like DARZALEX and ERLEADA, as well as new launches, though the segment experienced a significant decline in STELARA sales due to biosimilar competition. The MedTech segment also reported a 6.1% sales increase, driven by robust growth in Cardiovascular franchises, particularly from the Abiomed and Shockwave acquisitions, and steady performance in Surgery and Vision. However, the Orthopaedics business experienced modest growth, impacted by restructuring efforts and volume-based procurement in China. The company announced its intention to separate its Orthopaedics business, a move expected to be completed within 18-24 months, which may reshape its operational focus. Financially, Johnson & Johnson's earnings before taxes increased significantly, largely due to a favorable litigation outcome reversing a substantial portion of the talc reserve. The company also continues to manage its capital structure, with increased debt to fund strategic acquisitions like Intra-Cellular Therapies, Inc. (CAPLYTA), while also increasing its dividend for the 63rd consecutive year. Key risks remain, including ongoing litigation, increasing regulatory scrutiny, and the competitive landscape for key products.
Financial Highlights
54 data points| Revenue | $94.19B |
| Cost of Revenue | $30.26B |
| Gross Profit | $63.94B |
| R&D Expenses | $109.00M |
| SG&A Expenses | $23.68B |
| Operating Income | $26.80B |
| Net Income | $26.80B |
| EPS (Basic) | $11.13 |
| EPS (Diluted) | $11.03 |
| Shares Outstanding (Basic) | 2.41B |
| Shares Outstanding (Diluted) | 2.43B |
Key Highlights
- 1Total sales grew 6.0% to $94.2 billion in fiscal year 2025, driven by 8.4% volume growth.
- 2Innovative Medicine segment sales increased 6.0% to $60.4 billion, with Oncology performing strongly, though STELARA sales declined 41.3% due to biosimilar competition.
- 3MedTech segment sales rose 6.1% to $33.8 billion, led by a 15.8% increase in Cardiovascular, boosted by Abiomed and Shockwave acquisitions.
- 4The company announced plans to separate its Orthopaedics business, targeting completion within 18-24 months.
- 5Earnings before provision for taxes on income more than doubled to $32.6 billion, significantly aided by a $7.0 billion reversal of a talc reserve.
- 6Research and Development spending decreased by 14.9% to $14.7 billion, mainly due to lower acquired in-process R&D expenses compared to the prior year.
- 7Net debt increased to $27.8 billion due to acquisitions, while the company increased its dividend for the 63rd consecutive year.